Abstract:OBJECTIVE:To explore the strategy to raise both mucosal and systemic anti-HIV-1 immunity.METHODS:Eighteen BALB/c rats were randomly divided into 2 groups, experimental group and control group. The experimental group were further subdivided into 4 subgroups of 3 mice: 3-dose HIV DNA vaccine group, 3-dose DNA vaccine + cholera toxin (CT) adjuvant subgroup, 1-dose recombinant Tiantan strain vaccinia-based vaccine subgroup, and 3-dose DNA vaccine + CT adjuvant + Tiantan strain vaccinia-based vaccine subgroup. The control group was subdivided into 2 subgroups of 3 mice: 3-dose DNA blank vector subgroup, and 3-dose DNA blank vector + Tiantan strain vaccinia-based vaccine subgroup. Intranasal administration of DNA vaccine-based vaccine (10 microg) was done on the days 0, 14, and 28 as the mucosal priming, and recombinant Tiantan vaccinia (1 x 10(7) PFU) was injected intramuscularly as systemic boosting on the day 42. On the day 56 the mice were killed and specimens of serum, nasopharynx wash, lung wash, and spleen were collected and splenocytes were isolated. Splenocytes were added into the phosphate-buffered saline with anti-mouse interferon-gamma (IFN-gamma) envelop antibody to count the number of spot-forming cells (SFCs). Indirect ELISA was used to detect the HIV-1 specific antibody in the nasopharynx wash and lung wash. Immunohistochemistry was used to detect the intracellular staining of IFN-gamma in the splenocytes.RESULTS:The number of spot forming cells in the HIV-1 DNA vaccine + CT adjuvant group was (14 +/- 11) SFCs/10(6) splenocytes, significantly more than that of the HIV-1 DNA vaccine group [(2 +/- 1) SFCs/10(6) spleen cells (P < 0.01). The number of SFCs of the 1-dose DNA-vaccine subgroup was [(30 +/- 18) SFCs/10(6) spleen cells], significantly higher than that of the only DNS vaccine group (P < 0.01). The number of SFCs of DNA vaccine + CT adjuvant + recombinant Tiantan vaccinia-based vaccine was (61 +/- 35) SFCs/10(6) splenocytes, significantly higher than those of the other groups (all P < 0.01). Flow cytometry showed that the rate of HIV-1 Gag specific CD8(+) T cell was 1.8% +/- 1.4%. The value of specific IgG of the DNA vaccine + adjuvant + Tiantan vaccinia-based vaccine was 1.50 +/- 0.30, significantly higher than those of the blank vector, single-dose Tiantan vaccinia-based vaccine, and single-dose DNA vaccine + CT adjuvant subgroups (0.42 +/- 0.02, 0.74 +/- 0.13, and 0.75 +/- 0.02 respectively, all P < 0.05). In different subgroups the levels of specific IgA in the lung wash were all higher than those in the nasopharynx wash. The levels of specific IgA in the lung and nasopharynx wash of the DNA vaccine + CT adjuvant subgroup were higher than those of the other subgroups whether or not with boosting of Tiantan. The specific IgA levels of the groups enhanced by Tiantan vaccinia-based vaccine were all significantly higher than those of the corresponding subgroups without enhancement (all P < 0.01). The IgA level of lung wash of the DNA vaccine + CT adjuvant subgroup was 1.82 +/- 0.76, significantly higher than that of the one-dose Tiantan vaccinia-based vaccine group (0.52 +/- 0.19, P < 0.05).CONCLUSION:The vaccination modality of mucosal priming and systemic boosting induces both mucosal and systemic immune responses.

Interleukin-21 Administration Leads to Enhanced Antigen-Specific T Cell Responses and Natural Killer Cells in HIV-1 Vaccinated Mice

IL-17 As a Molecular Adjuvant on Enhancing Cellular Immune Responses to HIV DNA Vaccination

Interleukin-21 Inhibits Humoral Response to an HIV DNA Vaccine by Enhancing Bcl-6 and Pax-5 Expression

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

[The Immune Response in Mice Inoculated with HIV-1 Gag-Gp120 Chimeric Gene DNA Vaccine and IL-18 Plasmid].

Intranasal Priming with HIV DNA Vaccine and Systemic Boosting with Recombinant Vaccinia Induce Vigorous Immune Responses: Experiment with Mice

Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector.

Cytokine Adjuvants IL-7 and IL-15 Improve Humoral Responses of a SHIV LentiDNA Vaccine in Animal Models

Expression and Identification of Immunological Activities of the HIV‐gp120N‐Human Interferon Gamma Fusion Protein

Expression of recombinant plasmid of HIV-1 gp120 and IFN-gamma in E. coli and its immunoregulatory effect]

Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8+ T-cell avidity and protective immunity

Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence.

[Immune Response to HIV-2 Gp105 DNA Vaccine in Mice].

Eliciting Protective Immune Responses Against Murine Myeloma Challenge in Lymphopenia Mice Through Adoptive Transfer of Tumor Antigen-Specific Lymphocytes and Immunization of Tumor Vaccine Secreting Mil-21

Enhancement of SIV-specific Cell Mediated Immune Responses by Co-Administration of Soluble PD-1 and Tim-3 As Molecular Adjuvants in Mice

Construction and its Antitumor Efficiency of Murine Interleukin 21 Tumor Vaccine

Interleukin 21 Augments the Hepatitis B Virus-Specific CD8+ T-cell Response in Vitro in Patients Coinfected with HIV-1.

LL-37 antimicrobial peptide and heterologous prime-boost vaccination regimen significantly induce HIV-1 Nef-Vpr antigen- and virion-specific immune responses in mice

IL-21 level in Chinese HIV infected individuals and its dynamics undergoing HAART

Novel Oral Adjuvant to Enhance Cytotoxic Memory-Like NK Cell Responses in an HIV Vaccine Platform

Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses.